On the importance of culture, partnerships and diversity at the Dean’s Lecture Series

When pharmaceutical companies align their research endeavors with academic institutions, they are most likely to translate their findings quickly and safely into beneficial treatments for patients, said Emma Walmsley, CEO of GlaxoSmithKline, at a recent talk on campus as part of the Dean's Lecture Series. During their lunchtime conversation, which focused on organizational culture, diversity and the importance of partnerships, Dean Lloyd Minor, MD, shared Walmsley's enthusiasm for the collaboration between academia and industry.

Spotlight

PRMA Consulting Ltd

PRMA Consulting is a leading global consultancy offering pricing, reimbursement, and market access support for both therapeutic and preventive strategies.

OTHER ARTICLES
Pharma Tech

How long will the world wait for the next pandemic of antimicrobial resistance before we act?

Article | July 15, 2022

Antimicrobial resistance (AMR) has become an increasingly serious global health problem in recent years. World Health Organization (WHO) estimates that more than 700,000 people die each year due to drug-resistant infections, and the number is expected to increase in the coming years. How does antimicrobial resistance emerge? Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi, and parasites change over time and no longer respond to medicines. It makes infections harder to treat and increases the risk of disease, severe illness, and death. When we use antibiotics, some bacteria die, but resistant bacteria can survive and even multiply. The overuse of antibiotics and substandard antibiotics make resistant bacteria more common. So, the more we use antibiotics, the more chances bacteria have to become resistant to them. The rise in AMR is caused by multiple factors including the misuse and overuse of antibiotics by humans as well as in livestock and agriculture. Although these are the main drivers in the development of drug-resistant pathogens, the emergence of substandard and falsified antibiotics is another lesser-known, huge contributory factor. Even though AMR is a leading cause of death around the world, it is tracked most closely in clinical high-income settings and developed countries. Unfortunately, this is not the case in low and middle-income countries, where the highest burden is in low-resource settings and low-and middle-income countries (LMICs). These countries are disproportionately affected, in part due to the high burden of communicable diseases. Consequences to human health of AMR AMR poses significant risks to human health, resulting in prolonged and more severe infections, extended hospitalizations, and increased healthcare expenses. It can also lead to an increased risk of death, as an infection may become untreatable. Additionally, it can reduce the effectiveness of medicines and treatments, making it more difficult to manage existing medical conditions. It is even more concerning that it can lead to the emergence of new, more dangerous strains of bacteria, viruses, and other microbes. This would mean medical procedures, such as surgery, including caesarean sections or hip replacements, cancer chemotherapy, and organ transplantation, will become riskier. Counterfeit medicines and antibiotics: Antibiotics are the most counterfeited medicines in the world, as they account for 28% of global counterfeit medicines. Substandard and falsified antibiotics are medicines that do not meet the quality standards set by regulatory authorities. Counterfeit antibiotics are estimated at 5% of the global antibiotic market. These medicines are often of inferior quality or contain incorrect ingredients or incorrect amounts of active ingredients. They may also contain toxic contaminants or be expired, posing serious consequences for patients. Sadly, counterfeit antibiotics are mostly found in LMICs due to a lack of regulation and enforcement, as well as a lack of access to quality healthcare. In many of these countries, the demand for antibiotics is higher than the supply, and counterfeit antibiotics are seen as a cheaper and more accessible alternative. Furthermore, there is a lack of awareness around the dangers of taking counterfeit antibiotics, and there is a lack of resources for health authorities to test for the authenticity of these medicines. Why are antibiotics so rife for counterfeit drugs? Counterfeiters of pharmaceuticals succeed in large part by exploiting weaknesses in supply chains, which are often fragmented with poor regulatory frameworks. Antibiotics are often counterfeited because they are in high demand and can be sold for a large profit. To combat the problem of substandard and falsified antibiotics, governments must take a multi-pronged approach. This should encompass enacting laws and regulations to ensure the quality and safety of medicines, conducting surveillance for detecting and removing substandard and falsified products from the market, as well as providing training and education to healthcare professionals and patients regarding the responsible use of antibiotics. In addition, governments must work to strengthen the pharmaceutical supply chain. This includes increasing the transparency of the supply chain, improving the quality control systems, and introducing traceability systems to track the movement of medicines from the manufacturer to the patient. Medical investment in low and middle-income countries Another neglected aspect by international NGOs and governments is investment in building local laboratory capacity in LMICs to combat antimicrobial resistance. Localized laboratory facilities can help identify, track, and prevent the spread of antimicrobial-resistant infections, as well as provide early warnings of emerging drug-resistant strains. Localized microbiology, surveillance, and quality control laboratories can also play an important role in developing new treatments and interventions for combating antimicrobial resistance. In addition, having localized laboratory capacity can provide more accurate standardized data on the prevalence of drug-resistant infections, which can help inform policy decisions and public health interventions. Affordable medicines Finally, governments must work to increase access to high-quality, affordable medicines. This includes improving the availability of generic medicines, which are typically cheaper alternatives to brand-name drugs. They also need to increase access to newer, more effective antibiotics.

Read More
Pharma Tech

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | July 13, 2022

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More
Pharma Tech

What are the advantages of PCD Pharma Company?

Article | July 20, 2022

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | February 11, 2020

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

Spotlight

PRMA Consulting Ltd

PRMA Consulting is a leading global consultancy offering pricing, reimbursement, and market access support for both therapeutic and preventive strategies.

Related News

Inside plan to grow marijuana in Uganda

monitor | April 21, 2019

Different entities and individuals are fighting over the control of Uganda’s prospective medicinal cannabis industry, with a section of government officials reportedly fronting a number of companies to cash in on the multi-billion dollar business. Several entities with connections to already established companies in Europe and North America have been lined up by different officials as the government ponders a dive into the lucrative but dicey business. There is also a fight between several entities of government on who should take the lead in directing to the different investors lining up to engage in the lucrative business estimated to be worth $3b (about Shs11.1 trillion) when it commences. Among the entities that would be involved in licensing the entire chain are the ministries of Health, Agriculture, Justice and Constitutional Affairs and Internal Affairs; the National Drug Authority (NDA) and Uganda Investment Authority (UIA). The use of cannabis for recreational purposes such as smoking remains illegal in the country. Authorities are, however, exploring its production for medical purposes subject to authorisation by relevant government bodies in line with the Narcotic Drug and Pyschotropic Substances (Control) Act 2015.

Read More

Project aims to revive natural product discovery

eurekalert | April 23, 2019

The mid-20th century was the golden age of natural product discovery. Scientists discovered ground-breaking drugs, like penicillin and tetracycline, from sources in nature. But as the search for natural products continued, pharmaceutical companies kept finding the same products over and over again. By the early 2000s, most of these companies shut down their natural product discovery programs. At the same time, the era of genomics emerged. Instead of looking for natural products, scientists were now able to use genetic information to understand how natural products were made. This brought success in discovering new natural products, but only on a very small scale. Now, a new project aims to discover new natural products on a large scale by using synthetic biology and automation.

Read More

Dr Reddy's gets Chinese regulator nod for anti-blood clotting drug

business-standard | April 23, 2019

Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems. Hyderabad-based Dr Reddy’s Laboratories (DRL), which is betting big on the Chinese drug market, recently got an approval for a $1.6-billion anti-blood clotting drug from the Chinese regulator after an 11-year wait. Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems. The launch of the product is still some time away. This would be DRL’s biggest product in China in terms of market potential. The drug is now undergoing generic equivalent assessment (China requires drugmakers to conduct bioequivalence studies).

Read More

Inside plan to grow marijuana in Uganda

monitor | April 21, 2019

Different entities and individuals are fighting over the control of Uganda’s prospective medicinal cannabis industry, with a section of government officials reportedly fronting a number of companies to cash in on the multi-billion dollar business. Several entities with connections to already established companies in Europe and North America have been lined up by different officials as the government ponders a dive into the lucrative but dicey business. There is also a fight between several entities of government on who should take the lead in directing to the different investors lining up to engage in the lucrative business estimated to be worth $3b (about Shs11.1 trillion) when it commences. Among the entities that would be involved in licensing the entire chain are the ministries of Health, Agriculture, Justice and Constitutional Affairs and Internal Affairs; the National Drug Authority (NDA) and Uganda Investment Authority (UIA). The use of cannabis for recreational purposes such as smoking remains illegal in the country. Authorities are, however, exploring its production for medical purposes subject to authorisation by relevant government bodies in line with the Narcotic Drug and Pyschotropic Substances (Control) Act 2015.

Read More

Project aims to revive natural product discovery

eurekalert | April 23, 2019

The mid-20th century was the golden age of natural product discovery. Scientists discovered ground-breaking drugs, like penicillin and tetracycline, from sources in nature. But as the search for natural products continued, pharmaceutical companies kept finding the same products over and over again. By the early 2000s, most of these companies shut down their natural product discovery programs. At the same time, the era of genomics emerged. Instead of looking for natural products, scientists were now able to use genetic information to understand how natural products were made. This brought success in discovering new natural products, but only on a very small scale. Now, a new project aims to discover new natural products on a large scale by using synthetic biology and automation.

Read More

Dr Reddy's gets Chinese regulator nod for anti-blood clotting drug

business-standard | April 23, 2019

Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems. Hyderabad-based Dr Reddy’s Laboratories (DRL), which is betting big on the Chinese drug market, recently got an approval for a $1.6-billion anti-blood clotting drug from the Chinese regulator after an 11-year wait. Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems. The launch of the product is still some time away. This would be DRL’s biggest product in China in terms of market potential. The drug is now undergoing generic equivalent assessment (China requires drugmakers to conduct bioequivalence studies).

Read More

Events